IPO Edge hosted a fireside chat with Jupiter Neurosciences’ CEO Christer Rosen and President Alison Silva. They discussed the company’s treatments for neuroinflammation and rare diseases, as well as their clinical pipeline with $50B+ market opportunities. Watch the full interview for more insights.

Christer Rosen is the Co-Founder, CEO, and Chairman of Jupiter Neurosciences, with a background in pharmaceuticals and a degree in Computer Sciences. Alison Silva, the President and Chief Business Officer, has extensive experience in drug development, probiotics, and orphan drug strategy.

Jupiter Neurosciences is a pharmaceutical company focused on neuroinflammation and healthy aging. They have a therapeutic pipeline for CNS disorders and rare diseases, and also offer a consumer product line called Nugevia. Powered by their proprietary JOTROL formulation, Jupiter aims to bring clinical-grade science to the supplement market.

For more information about Jupiter Neurosciences and their innovative approaches to neuroinflammation and healthy aging, visit their website. Stay updated with the latest news and developments by subscribing to their weekly newsletter. Contact IPO Edge for more details or follow them on LinkedIn for regular updates.

Read more at Yahoo Finance: Jupiter Neurosciences CEO Christer Rosen & President Alison Silva, Live at Nasdaq